Phosphodiesterase 5 inhibitors

被引：22
|
作者：
Stamford, AW [1 ]
机构：
[1] Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA
来源：
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 37 | 2002年 / 37卷
关键词：
D O I：
10.1016/S0065-7743(02)37007-6
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
引用
收藏
页码：53 / 64
页数：12
相关论文
共 50 条
  • [31] ADMET considerations for phosphodiesterase-5 inhibitors
    Rezvanfar, Mohammad Amin
    Rahimi, Hamid Reza
    Abdollahi, Mohammad
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (10) : 1231 - 1245
  • [32] Cardiac Uses of Phosphodiesterase-5 Inhibitors
    Schwartz, Bryan G.
    Levine, Laurence A.
    Comstock, Gary
    Stecher, Vera J.
    Kloner, Robert A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (01) : 9 - 15
  • [33] Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction
    Aversa, Antonio
    Bruzziches, Roberto
    Pili, Marcello
    Spera, Giovanni
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (27) : 3467 - 3484
  • [34] Chronic dosing of phosphodiesterase type 5 inhibitors
    Donatucci C.F.
    Current Sexual Health Reports, 2008, 5 (2) : 65 - 69
  • [35] Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
    Tegos, George
    FRONTIERS IN PHARMACOLOGY, 2013, 4
  • [36] Phosphodiesterase type 5 inhibitors for erectile dysfunction
    Carson, CC
    Lue, TF
    BJU INTERNATIONAL, 2005, 96 (03) : 257 - 280
  • [37] Phosphodiesterase Type 5 Inhibitors: Unmet Needs
    Hatzimouratidis, K.
    Hatzichristou, D. G.
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (30) : 3476 - 3485
  • [38] Phase 4 Studies on Phosphodiesterase 5 Inhibitors
    VanderBeek, Brian L.
    Maguire, Maureen G.
    JAMA OPHTHALMOLOGY, 2022, 140 (05) : 484 - 485
  • [39] The use of phosphodiesterase 5 inhibitors with concomitant medications
    G. Corona
    E. Razzoli
    G. Forti
    M. Maggi
    Journal of Endocrinological Investigation, 2008, 31 : 799 - 808
  • [40] Phosphodiesterase 5 inhibitors: Pharmacology and therapeutic perspectives
    Barbaro, Giuseppe
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (27) : 3437 - 3437
12345